**Core Concept**
The patient's prolonged activated partial thromboplastin time (aPTT) indicates a coagulation pathway defect, specifically involving the intrinsic or common coagulation pathway. Von Willebrand disease is a genetic disorder affecting the von Willebrand factor (VWF), a crucial protein involved in platelet adhesion and coagulation factor VIII stabilization.

**Why the Correct Answer is Right**
The patient's abnormal bleeding time, coupled with a normal prothrombin time (PT), suggests a platelet-related issue, which is further confirmed by the elevated platelet count. This points towards a qualitative platelet defect, as seen in von Willebrand disease. Desmopressin (DDAVP) is a synthetic analogue of vasopressin, which stimulates the release of VWF from storage sites in endothelial cells, thereby correcting the bleeding time in patients with type 1 von Willebrand disease.

**Why Each Wrong Option is Incorrect**
**Option A:** Fresh frozen plasma (FFP) would not be effective in correcting the bleeding time, as it lacks a significant amount of VWF. FFP is more suitable for correcting PT and aPTT abnormalities due to coagulation factor deficiencies.
**Option B:** Platelet transfusion would not address the underlying VWF deficiency, and it may even lead to an adverse reaction in patients with von Willebrand disease.
**Option C:** Cryoprecipitate contains high levels of VWF, but its use is not indicated in type 1 von Willebrand disease, as it can cause thrombotic complications.

**Clinical Pearl / High-Yield Fact**
Desmopressin is a first-line treatment for mild to moderate von Willebrand disease, as it stimulates the release of VWF from storage sites in endothelial cells, thereby correcting the bleeding time.

**Correct Answer:** D. Desmopressin (DDAVP)